Tessera Defense & Homeland Security Inc. (HLSQ)
Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.
Sector: Services-Prepackaged Software
Industry: Biotechnology
OTC:HLSQ
Tessera Defense & Homeland Security Inc. (HLSQ) dilution facts from SEC filings
Snapshot as of Jun 30, 2026, built from 49 SEC filings.
- Warrants outstanding
- 12 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.